3 Pharma Stocks on Radar: Dr. Reddy's, Aurobindo get USFDA 483s; Biocon inks global deal

• Dr. Reddy's Laboratories received a USFDA Form 483 with five observations for its Srikakulam formulation facility.
• Aurobindo Pharma's subsidiary, Apitoria Pharma, also received a USFDA Form 483 with three observations for its API manufacturing facility.
• Biocon Biologics, a subsidiary of Biocon, secured a global settlement and licensing agreement with Regeneron and Bayer for biosimilar Aflibercept (Yesafili).
• This agreement allows Biocon Biologics to launch Yesafili globally, with plans for a UK launch in January 2026 and other markets by March 2026.

Why It Matters: Regulatory scrutiny and a global licensing deal will shape key pharma stocks' future.